SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Carney Warns Canada Must Rethink U.S. Ties Amid Trade Tensions and Sovereignty Concerns 
This fuel crisis could last for a while. It’s time for a new approach to fuel use - end it 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey 
Oil Prices Surge Amid U.S.-Iran Tensions and Strait of Hormuz Disruptions 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Asian Currencies Slip as Dollar Gains Safe-Haven Strength Amid U.S.-Iran Tensions 
Asian Currencies Stay Range-Bound as Dollar Holds Steady Ahead of Fed Nominee Hearing 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
A team of Japanese scientists has developed a method that utilizes glucose and fragmented antibodies in reducing an abnormal accumulation of protein in the brains of mice with Alzheimer’s disease.
According to Takanori Yokota, a neurology professor at the university who was part of the team, they hope accomplishment will lead to the development of a new therapy that is safer and more efficient than its conventional antibody-used counterpart.
The amyloid beta protein accumulation in the brain is believed to trigger Alzheimer’s.
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine (iCONM), encapsulated fragments of an antibody that can attach itself to the protein and remove it from the brain into a so-called nanomachine.
They also attached glucose molecules to the nanomachine's surface, making it simpler for the brain to receive the antibody.
The mice with abnormally high levels of amyloid beta due to the disease were given injections of the encapsulated antibody fragments by the researchers. The agent was administered weekly for 10 weeks.
In contrast to just injecting them there, the study found that employing a nanomachine can deliver 80 times more antibody fragments to the brain.
It was also established that this technique can be used to get rid of amyloid beta lumps, which prevented the protein from gathering.
Because a whole antibody is too large to be placed in many places, the researchers chose to employ antibody fragments instead.
The result was a positive effect that was unanticipated.
Historically, the blood-brain barrier, which determines what to take in from blood vessels to protect the brain, prevented the entire prescribed medication to eliminate the protein from reaching the brain.
Therapeutic antibodies for Alzheimer's disease are well known for having undesirable side effects, such as inflamed brain swelling.
As the fragmented antibody lacks the portion that causes inflammatory reactions, the team anticipates that this side effect may be avoided.
